First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

NCT06517433 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum Resistant Ovarian Cancer
Non Small Cell Lung Cancer Metastatic

Interventions

DRUG: upifitamab rilsodotin

Sponsor

Mersana Therapeutics